A Phase I, First-in-Human, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2373 Following Single Ascending Dose Administrations to Healthy Male Subjects of African Ancestry
Latest Information Update: 11 Jul 2023
At a glance
- Drugs AZD 2373 (Primary)
- Indications Kidney disorders
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
Most Recent Events
- 05 Jan 2023 Status changed from discontinued to completed.
- 20 Sep 2021 Status changed from active, no longer recruiting to discontinued AZ has decided not to continue this study, since sufficient data are available to supportproposed dosing in future studies, and assessment of higher single doses are limited by tolerability due to the development of Injection Site Reactions. .
- 18 Jun 2021 Status changed from recruiting to active, no longer recruiting.